ISHARES DOW JONES US MEDICAL DEV.(ETF) (IHI)…

Home

Daily Stock Opinions and Ratings

ISHARES DOW JONES US MEDICAL DEV.(ETF) (IHI)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

50.71

+0.85 (1.70%)

as of Jun 9, 2026, 2:58:34 pm Market Open.

64 watching

Investor Insights

Jun 9, 2026, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

The healthcare sector, represented by the ISHARES DOW JONES US MEDICAL DEV. (ETF) IHI-N, is currently underperforming, noted as the worst-performing sector this year, presenting a potential value opportunity. Despite challenges such as inflation and market volatility, healthcare investments are seen as insulated from interest rate fluctuations, making them more attractive in uncertain economic conditions. Specifically, healthcare equipment and services are highlighted as a safer bet amid concerns about pharmaceutical policies. Therefore, IHI presents a potentially strategic purchase for those looking to invest in a value-oriented environment, as the industry's fundamentals may promise recovery.

Consensus

Buy

Valuation

Undervalued

Similar

MDT

PAST TOP PICK

(A Top Pick Jun 08/18, Up 11%) He continues to love holding this. Worldwide hospital spending continues to increase.

BUY

He likes this. Medical devices play to an aging demographic. The risk is political intereference with governments issuing new laws that interfere with this sector.

PAST TOP PICK

(A Top Pick May 09/18, Up 16%) He sees this continuing to be a good performer. It will follow the market up and down, but will do a little better in the long run. The ETF helps reduce the risk of picking a single company. He has backed away from healthcare, but still still holds this.

PAST TOP PICK

(A Top Pick Apr 11/18, Up 25%) It is high quality with a 1.0 beta. He would stick with it as the fundamental still hold true -- aging population, diabetes, etc. There are 29 million US adults with Type 2 diabetes and another 84 million are pre-diabetic -- almost 1 in 3 adults.

BUY

He likes because it gives diversification away from the big pharma. Nothing wrong with this one.

BUY

IXJ vs. IHI IXJ is well-diversified and global and prefers this to IHI. It has an overlay of healthcare technology, which is exciting particularly technology. IHI is fine, too. Buy one-third IXJ and one-third IHI.

BUY

PAST TOP PICK

(A Top Pick Nov 23/18, Up 6%) Nov.25-Feb.14 is seasonality which coincides with several healthcare conferences. These medical stocks are still outperforming the market. He took profits.

COMMENT

What comes screaming back is the previous leaders. There is persistence. Internet retail is the first one to break down and the first one to reverse. Basic materials are the area starting to make a turn. It would be complimentary to add some Canada.

TOP PICK

He likes the end-market growth story -- knees, hips, joints, etc. High-quality with a high market beta -- this is not a defensive ETF. A broad basket with a diversified portfolio. Yield 0.36%

PAST TOP PICK

(A Top Pick Jan 11/18, Up 8%) Likes it. There are really two robust parts of the healtcare sector, one is this one, medical devices and equipment, and the other is managed care. You are buying market beta here; if the market goes down, IHI is going down. They might be high quality and good cash flow, but don't think of this as safety. Loves it and would stick with it.

TOP PICK

Healthcare has performed phenomally this year, avoiding cyclical breakdowns found in other sectors. Seasonally, it's Nov.24-Feb.14. Aging demographics help, but really pushes this are all the healthcare conferences at the start of the year. These stocks run up till then.

TOP PICK

He likes medical devices – worldwide hospital spending, changing demographics. It has great tailwinds. They are less politically charged than drug prices.

TOP PICK

He likes the healthcare space. This is a high-quality beta play in the space. Don’t expect it to be super defensive, but thinks global hospital spending will continue to rise.

TOP PICK

It's feeding into the demographic of aging baby boomers. This includes medical devices like Abbott Labs. Also likes it because it's U.S. and diversifies from big pharma.

Showing 16 to 30 of 45 entries

Most Recent Experts

Barry Schwartz

Baskin Wealth Management

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Brian Madden

First Avenue Investment Counsel

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

ISHARES DOW JONES US MEDICAL DEV.(ETF) (IHI)